newsfilter
← Latest News
GlobeNewswire·

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of